Clinical trials: Diabetic Nephropathies, open to volunteers
Diabetic Nephropathy Type 2
Human Umbilical Cord Mesenchymal Stem Cell Infusion for Type 2 Diabetic Nephropathy
Diabetic nephropathy (DN) is a chronic kidney disease caused by diabetes. It is one of the most common and most serious microvascular complications of diabetes. Current treatment options for DN are limited.
- Trial name
- NCT07769671
- Testing
- Human umbilical cord mesenchymal stem cell injection
- Where
- China
- Volunteers
- 49 people
- Sponsor
- The First People's Hospital of Changzhou
Diabetic Kidney Disease
Efficacy and Safety of LC-Z300-01 on Proteinuria in Diabetic Patients
The purpose of this RCT is to investigate the efficacy and safety of Sugar cane polysaccharide LC-Z300-01 on proteinuria in participants with diabetic kidney disease (DKD).
- Trial name
- NCT06686758
- Testing
- Sugar cane polysaccharide, Control
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Changzheng Hospital
Diabetic Kidney Disease, Chronic Kidney Diseases
A Long-Term Follow-Up Study of Participants Exposed to REACT
The purpose of this study is to evaluate the long-term safety of up to two gelatin-hydrogel formulation REACT injections given 3 to 6 months apart and delivered percutaneously into same kidney on renal function in participants…
- Trial name
- NCT05918523
- Testing
- Renal Autologous Cell Therapy (REACT)
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Prokidney
Diabetic Wounds, Platelet Rich Plasma
Allogeneic vs Autologous PRP for Diabetic Wounds in Renal Dysfunction: a Randomized Controlled Trial
Diabetic wounds are difficult to heal. Autologous platelets in diabetic patients with renal insufficiency have poor function. Allogeneic platelet plasma has a promising application prospect.
- Conditions
- Diabetic Wounds, Platelet Rich Plasma, Allogeneic Blood Transfusions, Renal Dysfunction
- Trial name
- NCT07020559
- Testing
- allogeneic platelet plasma, autologous platelet plasma
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Peking University Third Hospital
Diabetic Kidney Disease (DKD)
YiqiJiangzhuoHuoxueTongluo Method to Delay the Occurrence of End-stage Renal Disease in Diabetic Kidney Disease--Study1
In order to reduce the clinical demand for kidney dialysis rate of Diabetic Kidney Disease（DKD） patients, a bidirectional cohort study of 4472 patients with DKD (Qi deficiency and collateral stasis syndrome) was carried out based…
- Trial name
- NCT07032116
- Where
- 5 sites in China
- Volunteers
- 4,472 people
- Sponsor
- Liu Hongfang
Diabetic Nephropathy Type 2
Relationship of Serum Zinc Level With Severity of Diabetic Nephropathy
Zinc influences the production and action of erythropoietin (EPO), a hormone produced by the kidneys that stimulates red blood cell production.
- Trial name
- NCT06690034
- Volunteers
- 92 people
- Sponsor
- Assiut University
Effect of SGLT2 Inhibitors NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy
Effect of SGLT2 Inhibitors on NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy
To rule out the beneficial effect of SGLT2-I to reduce liver fat, and change in inflammatory markers (ALT, AST) in type 2 diabetic patients with non-alcoholic fatty liver disease.
- Trial name
- NCT06668753
- Testing
- Dapagliflozin 10mg Tab or Empagliflozin 10 mg Tab
- Volunteers
- 114 people
- Sponsor
- Assiut University
Diabetic Nephropathy Type 2, Biomarker
Screening and Application Research of Early Diabetic Nephropathy Markers Based on Lipidomics.
Diabetic nephropathy (DN) is one of the major microvascular complications associated with diabetic patients, and also the major global cause of chronic kidney disease and end-stage renal disease (ESRD).
- Trial name
- NCT04931537
- Where
- China
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Diabetes Mellitus, Bariatric Surgery Candidate
Paraoxonase and HDL Qualities in Glycaemia and Inflammation
The incidence of coronary heart disease (CHD) is significant in the super-obese and diabetics. Inflammation is believed to play an important part in the development of CHD, and the large collection of abdominal fat in the obese…
- Trial name
- PON1 (NCT02169518)
- Where
- United Kingdom
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Manchester University NHS Foundation Trust
Diabetes Mellitus, Type 2, Cardiovascular Diseases
Clinical Utility of a Genomic Predictor Test on the Management of Cardiorenal Complications of Type 2 Diabetes
The goal of this pragmatic trial is to provide Real World Evidence (RWE) on the impact of the result of a polygenic risk prediction test of cardiorenal complications of T2D, so that more patients at high risk of these…
- Conditions
- Diabetes Mellitus, Type 2, Cardiovascular Diseases, Diabetic Nephropathy Type 2
- Trial name
- GENOCORDIA (NCT06586203)
- Testing
- Polygenic Risk Score
- Where
- 2 sites in Canada
- Volunteers
- 2,714 people
- Sponsor
- Optithera
Lead-Burdened Type 2 Diabetic Nephropathy
Intravenous Chelators in Lead-Burdened Type 2 Diabetic Nephropathy
Based on previous basic experiments revealing that patients with type 2 diabetic nephropathy exhibit higher blood lead levels than the general population, this study aims to systematically evaluate the impacts of short-term and…
- Trial name
- NCT07706946
- Testing
- chelator
- Volunteers
- 42 people
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Diabetic Kidney Disease (DKD)
Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease
This study is researching an experimental drug called ALN-ANG3 (called "study drug"). The study is focused on participants who have diabetic kidney disease.
- Trial name
- ANCHOR-POC (NCT07271186)
- Testing
- ALN-ANG3, Evinacumab
- Where
- 59 sites in United States
- Volunteers
- 195 people
- Sponsor
- Regeneron Pharmaceuticals
Type 2 DM, Type 2 DM /Diabetic Nephropathy
Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study
Title: Body fluid proteome SIGnatures for persoNALised intervention to prevent cardiovascular and renal complications in diabetes.
- Conditions
- Type 2 DM, Type 2 DM /Diabetic Nephropathy, Albuminuria
- Trial name
- SIGNAL (NCT06954090)
- Testing
- Semaglutide, 1.34 mg/mL, Finerenone Oral Tablet, Dapagliflozin (DAPA)
- Where
- Denmark
- Volunteers
- 50 people
- Sponsor
- Steno Diabetes Center Copenhagen
Diabetic Kidney Disease
Multimodal Magnetic Resonance Imaging in Evaluation of Diabetic Kidney Disease
The goal of this study is to investigate the value of noninvasive evaluation of multimodal magnetic resonance imaging in diagnosis and treatment of diabetic kidney disease (DKD).
- Trial name
- NCT06452862
- Testing
- Magnetic Resonance Imaging
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Shengjing Hospital
Type 1 Diabetes Mellitus, Diabetic Ketoacidosis
Biomarkers of Acute Organ Injury in Pediatric Newly Diagnosed Type 1 Diabetes
Diabetic ketoacidosis (DKA) is a severe metabolic complication in children with newly diagnosed type 1 diabetes mellitus (T1DM) and may be associated with early injury of vital organs such as the kidneys and the heart.
- Trial name
- NCT07483879
- Testing
- Biomarker and Echocardiographic Assessment
- Where
- Greece
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Aristotle University Of Thessaloniki
Diabetic Nephropathy
Lactoferrin Supplementation in Diabetic Nephropathy
Multiple pathways and mediators, including oxidative stress, inflammation, and the over-activity of the renin-angiotensin-aldosterone system are involved in the development of albuminuria and progression of diabetic nephropathy…
- Trial name
- NCT07764991
- Testing
- Lactoferrin, Antidiabetic
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Ain Shams University
Diabetic Kidney Disease, Type 1 Diabetes
Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes
The primary objective of this study is to determine the effects of semaglutide on change in albuminuria from baseline to 26 weeks in type 1 diabetes.
- Trial name
- RT1D (NCT05822609)
- Testing
- Semaglutide
- Where
- 4 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- University of Washington
Diabetic Nephropathy Type 2, Chronic Renal Failure/ Kidney Disease
Research on Innovative Traditional Chinese Medicine Diagnosis and Treatment Technologies for Diabetic Nephropathy Driven by Multi-Omics and Artificial Intelligence
With the help of the 'Traditional Chinese Medicine Specialty Alliance Platform-Multicenter RCT Clinical Research Database,' this platform can be used to conduct scientific research on various aspects of DKD, such as disease…
- Trial name
- NCT07459946
- Testing
- Jiajian Yishen Xiaozheng Qufeng Granules
- Volunteers
- 198 people
- Sponsor
- Jiazhen Yin
Diabetic Nephropathy Type 2
Study of the Protective Effect of Low-dose Aspirin on Renal Function in Patients With Early Diabetic Nephropathy
This is a multicenter, randomized, placebo-controlled study to evaluate the effectiveness and safety of low-dose aspirin (50 mg/day) in renal and cardiac function protection in people with diabetic nephropathy.
- Trial name
- NCT06068439
- Testing
- Acetylsalicylic Acid
- Volunteers
- 355 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Diabetic Nephropathy Type 2, Diabetic Kidney Disease
Multidimensional Accurate Diagnosis and Treatment Technology and Clinical Transformation of Type 2 Diabetes Nephropathy
Diabetes nephropathy (DN) is one of the most serious microvascular complications of diabetes, and also an important cause of death and disability of diabetes patients.
- Conditions
- Diabetic Nephropathy Type 2, Diabetic Kidney Disease, Type 2 Diabetes
- Trial name
- NCT05888909
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Chinese PLA General Hospital